U.S. markets closed
  • S&P 500

    -38.76 (-1.02%)
  • Dow 30

    -346.93 (-1.15%)
  • Nasdaq

    -75.33 (-0.68%)
  • Russell 2000

    -10.18 (-0.58%)
  • Crude Oil

    +1.20 (+1.37%)
  • Gold

    +0.10 (+0.01%)
  • Silver

    +0.15 (+0.71%)

    -0.0089 (-0.90%)
  • 10-Yr Bond

    +0.0670 (+1.78%)

    -0.0154 (-1.36%)

    +0.4880 (+0.34%)

    -102.15 (-0.51%)
  • CMC Crypto 200

    -7.01 (-1.51%)
  • FTSE 100

    -55.35 (-0.78%)
  • Nikkei 225

    +190.80 (+0.70%)

INVENT Ventures Portfolio Company Sanguine to Begin Work with Mayo Clinic Bioservices

Collaboration to Accelerate Individualized Medicine R&D and Improve Patient Engagement

SANTA MONICA, Calif. / ACCESSWIRE / May 19, 2014 / INVENT Ventures (IDEA), a venture firm that builds, manages, and invests in early-stage web and mobile technology companies, announced today that its portfolio company Sanguine Biosciences, Inc. (“Sanguine”) has secured an agreement with Mayo Clinic Bioservices.

Under this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens collected by Sanguine for the purpose of developing new therapies. Mayo Clinic Bioservices will provide integrated laboratory services including specimen accessioning, processing, nucleic acid extraction, specimen tracking, storage and shipping. Mayo Clinic Bioservices is a new service from the Mayo Clinic Center for Individualized Medicine.

"Partnering with Mayo Clinic Bioservices dramatically increases the scalability of the Sanguine's business and furthers the company in its goal of improving efficiency in the development of personalized medical research," said Bryce Knight, CEO of INVENT Ventures. "Not only does this partnership benefit Sanguine and its clients which include 20 of the top 40 pharmaceutical and biotechnology companies, but more importantly it allows patients on its waiting list to participate in the research and development of new treatments."

Click here to access the full the press release - Sanguine to begin work with Mayo Clinic Bioservices.

About Sanguine

Sanguine is a technology company providing services to the personalized medicine and biomedical research market by efficiently collecting and providing biological specimens and data to companies and institutions developing new therapeutic solutions. The Company has developed a mobile application that enables medical technicians to locally collect blood samples and medical data directly from individuals interested in advancing the understanding and treatment of disease in the comfort of individuals' homes, as opposed to within the physician's office or hospital, an inefficient process that is currently delaying pharmaceutical research projects. For more information, please visit https://www.sanguinebio.com/.

About INVENT Ventures, Inc.

INVENT Ventures, Inc. (IDEA) is a venture firm that builds, manages, and invests in early-stage web and mobile technology companies. INVENT is headquartered in Santa Monica, California in the dynamic Silicon Beach area. For more information on INVENT, visit http://www.invent.vc/.

Safe Harbor Statement

Certain statements contained in this document that are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. The words or phrases "will likely result," "are expected to," "will continue," "is anticipated," "believes," "estimates," "projects" or similar expressions are intended to identify these forward-looking statements. These statements are subject to risks and uncertainties beyond our reasonable control that could cause our actual business and results of operations to differ materially from those reflected in our forward-looking statements. The safe harbor provisions provided in the Securities Litigation Reform Act do not apply to forward-looking statements we make in this document. Forward-looking statements are not guarantees of future performance. We based our forward-looking statements on our current

expectations about future events. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee you that these expectations actually will be achieved. We are under no duty to update any of the forward-looking statements after the date of this filing to conform those statements to actual results. In evaluating these statements, you should consider various factors, including the Risk Factors.

Investor and Media Contact:

Robert Haag